China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

Medicines regulators have cleared Innovent Biologics's anti-PD-1 therapy, sintilimab, for classical Hodgkin's lymphoma in China, where late-stage studies as a first-line therapy for advanced esopheageal cancer have also just started.